Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Mar-Apr;25(2):143-9.
doi: 10.5144/0256-4947.2005.143.

Anthrax vaccines

Miroslav Splino  1 , Jiri Patocka, Roman Prymula, Roman Chlibek
Affiliations
Review

Anthrax vaccines

Miroslav Splino et al. Ann Saudi Med. 2005 Mar-Apr.

Abstract

Anthrax, an uncommon disease in humans, is caused by a large bacterium, Bacillus anthracis. The risk of inhalation infection is the main indication for anthrax vaccination. Pre-exposure vaccination is provided by an acellular vaccine (anthrax vaccine adsorbed or AVA), which contains anthrax toxin elements and results in protective immunity after 3 to 6 doses. Anthrax vaccine precipitated (AVP) is administered at primovaccination in 3 doses with a booster dose after 6 months. To evoke and maintain protective immunity, it is necessary to administer a booster dose once at 12 months. In Russia, live spore vaccine (STI) has been used in a two-dose schedule. Current anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever). Serious adverse reactions occur in about 1% of vaccinations. New second-generation vaccines in current research programs include recombinant live vaccines and recombinant sub-unit vaccines.

PubMed Disclaimer

References

    1. Merka V, Patocka J. Anthrax: an important agent of biological terrorism. Nederl Milit Geneesk T. 2002;55:142–145.
    1. Prymula R, Splino M, Chlibek R, Beran J, Fusek J, Bajgar J. Biological and Chemical Terrorism. Prague: Grada Publishing; 2002. (In Czech)
    1. Splino M, Patocka J. Prophylaxis against anthrax. Acta Medica. 2002;45:85–88. - PubMed
    1. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. JAMA. 1999;281:1735–1745. - PubMed
    1. Friedlander AM. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis. 2000;20:335–349. - PubMed

Substances